Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 1;108(1):240-244.
doi: 10.3324/haematol.2022.281386.

Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population

Camille C B Kockerols  1 , Jeroen J W M Janssen  2 , Nicole M A Blijlevens  3 , Saskia K Klein  4 , Laura G M Van Hussen-Daenen  5 , Gwendolyn G Y Van Gorkom  6 , Willem M Smit  7 , Peter Van Balen  8 , Bart J Biemond  9 , Marjan J Cruijsen  10 , Maarten F Corsten  11 , Peter A W Te Boekhorst  12 , Harry R Koene  13 , Geerte L Van Sluis  14 , Jan J Cornelissen  12 , Peter E Westerweel  15
Affiliations

Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population

Camille C B Kockerols et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative incidences of MR1.0 (BCR::ABL1 <10% IS), MR2.0 (BCR::ABL1 <1% IS), MMR (BCR::ABL1 <0,1% IS), MR4.0 (BCR::ABL1 <0,01% IS) in 44 chronic-phase chronic myeloid leukemia patients during asciminib treatment. A cumulative incidence competing risk (CICR) method was used for this response analysis, with asciminib discontinuation of any cause as competing event. IS: International Scale.
Figure 2.
Figure 2.
Overall best achieved response in chronic-phase patients, presented as proportions (%) in all patients and in patients without the respective response at baseline. CHR: complete hematological response; IS: International Scale.
See this image and copyright information in PMC

References

    1. Hughes TP, Mauro MJ, Cortes JE, et al. . Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315-2326. - PMC - PubMed
    1. Rea D, Mauro MJ, Boquimpani C, et al. . A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031-2041. - PMC - PubMed
    1. ASC4MORE trial. Available at: https://clinicaltrials.gov/ct2/show/NCT03578367
    1. CMLXI trial. Available at: https://clinicaltrials.gov/ct2/show/NCT03906292.
    1. Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14(1):44-49. - PMC - PubMed

MeSH terms